Movement Alert｜AstraZeneca PLC Pre-Market Rise 4.77%, Stock Recovers as Multiple Banks Question Feasibility of Bristol-Myers Squibb Merger

Market Focus08-05 20:05

On August 5, AstraZeneca PLC rose 4.77% in pre-market trading, trading at approximately $163.08/share, with turnover of $27.4 million. The stock is recovering from a sharp decline of over 9% earlier this week following reports of merger talks with Bristol-Myers Squibb.

Multiple investment banks have cast doubt on the proposed $400 billion combination. BMO Capital noted that neither company has sufficient financial capacity to acquire the other, estimating AstraZeneca could raise approximately $37 billion — far below the funds required. RBC Capital Markets stated the deal is unlikely as AstraZeneca shareholders broadly oppose the transaction, questioning the rationale and expressing concerns about growth dilution. Separately, AstraZeneca signed a joint venture contract with CSPC Pharmaceutical Group, sending a positive signal on business expansion.

With market expectations for the mega-merger cooling significantly, the previously oversold stock is experiencing a technical recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199191648?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199191648","market":"hk","top_or_hot":-1,"title":"Movement Alert｜AstraZeneca PLC Pre-Market Rise 4.77%, Stock Recovers as Multiple Banks Question Feasibility of Bristol-Myers Squibb Merger","media":"Market Focus","content":"<p><p>On August 5, AstraZeneca PLC rose 4.77% in pre-market trading, trading at approximately $163.08/share, with turnover of $27.4 million. The stock is recovering from a sharp decline of over 9% earlier this week following reports of merger talks with Bristol-Myers Squibb.</p><p>Multiple investment banks have cast doubt on the proposed $400 billion combination. BMO Capital noted that neither company has sufficient financial capacity to acquire the other, estimating AstraZeneca could raise approximately $37 billion — far below the funds required. RBC Capital Markets stated the deal is unlikely as AstraZeneca shareholders broadly oppose the transaction, questioning the rationale and expressing concerns about growth dilution. Separately, AstraZeneca signed a joint venture contract with CSPC Pharmaceutical Group, sending a positive signal on business expansion.</p><p>With market expectations for the mega-merger cooling significantly, the previously oversold stock is experiencing a technical recovery.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AstraZeneca PLC Pre-Market Rise 4.77%, Stock Recovers as Multiple Banks Question Feasibility of Bristol-Myers Squibb Merger</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AstraZeneca PLC Pre-Market Rise 4.77%, Stock Recovers as Multiple Banks Question Feasibility of Bristol-Myers Squibb Merger\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-05 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 5, AstraZeneca PLC rose 4.77% in pre-market trading, trading at approximately $163.08/share, with turnover of $27.4 million. The stock is recovering from a sharp decline of over 9% earlier this week following reports of merger talks with Bristol-Myers Squibb.</p><p>Multiple investment banks have cast doubt on the proposed $400 billion combination. BMO Capital noted that neither company has sufficient financial capacity to acquire the other, estimating AstraZeneca could raise approximately $37 billion — far below the funds required. RBC Capital Markets stated the deal is unlikely as AstraZeneca shareholders broadly oppose the transaction, questioning the rationale and expressing concerns about growth dilution. Separately, AstraZeneca signed a joint venture contract with CSPC Pharmaceutical Group, sending a positive signal on business expansion.</p><p>With market expectations for the mega-merger cooling significantly, the previously oversold stock is experiencing a technical recovery.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"","article_id":"1199191648","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199191648","pubTimestamp":1785931551,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 5, AstraZeneca PLC rose 4.77% in pre-market trading, trading at approximately $163.08/share, with turnover of $27.4 million. The stock is recovering from a sharp decline of over 9% earlier...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康"},"translate_title":"走势警报|阿斯利康公司盘前上涨 4.77%，多家银行质疑百时美施贵宝合并的可行性，股价反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"On August 5, AstraZeneca PLC rose 4.77% in pre-market trading, trading at approximately $163.08/share, with turnover of $27.4 million. The stock is recovering from a sharp decline of over 9% earlier this week following reports of merger talks with Bristol-Myers Squibb.Multiple investment banks have cast doubt on the proposed $400 billion combination. BMO Capital noted that neither company has sufficient financial capacity to acquire the other, estimating AstraZeneca could raise approximately $37 billion — far below the funds required. RBC Capital Markets stated the deal is unlikely as AstraZeneca shareholders broadly oppose the transaction, questioning the rationale and expressing concerns about growth dilution. Separately, AstraZeneca signed a joint venture contract with CSPC Pharmaceutical Group, sending a positive signal on business expansion.With market expectations for the mega-merger cooling significantly, the previously oversold stock is experiencing a technical recovery.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199191648","isCrawlerRequest":true}